抗生素被广泛用于治疗细菌感染,降低死亡率,而抗生素的过度使用会导致肠道微生物群失调。抗生素对肠道微生物群的影响尚未完全了解。在我们的研究中,四种常用的抗生素(头孢他啶,头孢哌酮-舒巴坦,亚胺培南-西司他丁,和莫西沙星)皮下给予小鼠,通过16SrRNA分析和多重免疫分析评估了它们对肠道菌群组成和血清细胞因子水平的影响。抗生素治疗显着降低肠道微生物群多样性并改变肠道微生物群组成。抗生素治疗显着增加和减少了厚壁菌和拟杆菌的丰度,分别。抗生素治疗增加了肠球菌等机会致病菌的丰度,并减少了Lachnospirosaceae和Muribaculaceae的丰度。对于莫西沙星,治疗14天和21天后观察到肠球菌和克雷伯菌的丰度显著较高.然而,亚胺培南-西司他丁治疗14天后发现相对较低的机会病原体丰度.此外,各种促炎细胞因子的血清水平,如IL-1β,IL-12(p70),和IL-17,在抗生素治疗21天后显著增加。总的来说,这些结果为临床合理使用抗生素提供了指导:建议短期使用莫西沙星,14天使用亚胺培南-西司他丁的影响可能不如其他抗生素严重。IMPORTANCE抗生素治疗与肠道微生物群的变化直接相关,并且对病原体和有益细菌均有效。抗生素治疗引起的肠道菌群失调可能会增加某些疾病的风险。因此,充分了解抗生素使用后肠道微生物群的变化至关重要.在这项研究中,我们研究了抗生素持续治疗对肠道菌群的影响,血清细胞因子,和肠道炎症反应。我们的结果表明,建议短期使用莫西沙星,与头孢哌酮-舒巴坦相比,14天使用亚胺培南-西司他丁对肠道微生物群健康的影响可能较小。这些结果为合理使用抗生素对肠道微生物群健康提供了有用的指导。
Antibiotics are widely used to treat bacterial infection and reduce the mortality rate, while
antibiotic overuse can cause gut microbiota dysbiosis. The impact of antibiotics on gut microbiota is not fully understood. In our study, four commonly used antibiotics (ceftazidime, cefoperazone-sulbactam, imipenem-cilastatin, and moxifloxacin) were given subcutaneously to mice, and their impacts on the gut microbiota composition and serum cytokine levels were evaluated through 16S rRNA analysis and a multiplex immunoassay.
Antibiotic treatment markedly reduced gut microbiota diversity and changed gut microbiota composition. Antibiotic treatment significantly increased and decreased the abundance of Firmicutes and Bacteroidota, respectively. The
antibiotic treatments increased the abundance of opportunistic pathogens such as Enterococcus and decreased that of Lachnospiraceae and Muribaculaceae. For moxifloxacin, the significantly high abundance of Enterococcus and Klebsiella was observed after 14 and 21 days of treatment. However, a relatively low abundance of opportunistic pathogens was found after 14 days of imipenem-cilastatin treatment. Additionally, the serum levels of various pro-inflammatory cytokines, such as IL-1β, IL-12 (p70), and IL-17, significantly increased after 21 days of antibiotic treatments. Overall, these results provide a guide for rational use of antibiotics in clinical settings: short-term use of moxifloxacin is recommended with regard to gut microbiota health, and the 14-day use of imipenem-cilastatin may have a less severe impact than other antibiotics.IMPORTANCEAntibiotic treatments are directly associated with changes in gut microbiota and are effective against both pathogens and beneficial bacteria. Gut microbiota dysbiosis induced by
antibiotic treatment could increase the risk of some diseases. Therefore, an adequate understanding of gut microbiota changes after
antibiotic use is crucial. In this study, we investigated the effects of continuous treatment with antibiotics on gut microbiota, serum cytokines, and intestinal inflammatory response. Our results suggest that short-term use of moxifloxacin is recommended, and the 14-day use of imipenem-cilastatin may have a less severe effect on gut microbiota health than cefoperazone-sulbactam. These results provide useful guidance on the rational use of antibiotics with regard to gut microbiota health.